Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

Fig. 2

Treatment of mRCC patients with sunitinib decreases platelet count and other hematological parameters over time. Blood was collected from 10 healthy controls and 20 mRCC patients the day before, after 2 weeks, 4 weeks and 3 months on sunitinib treatment. Hematological parameters were measured in whole blood. Scatterplots show (A) platelet count (PLT), (B) white blood cell count (WBC), (C) red blood cell count (RBC), (D) hemoglobin concentration (HGB) and (E) hematocrit levels (HCT). Individual dots in the scatterplots represent one patient, for color coding see Table 1. Lines and error bars represent median ± interquartile range (n = 10-20). *P < 0.05. **P < 0.01, ***P < 0.001

Back to article page